Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.
Novartis's new treatment for hives outperforms Xolair in trials
![Novartis's new treatment for hives outperforms Xolair in trials]()
Reviewed by jenisht
on
December 04, 2018
Rating:
No comments: